Novo Nordisk stock eases as share buybacks and AI deal set up strategy update

Novo Nordisk stock (ISIN DK0062498333) is trading below recent highs as investors weigh ongoing share buybacks and a new artificial intelligence collaboration against softer short-term performance as of mid-September 2026. As Simply Wall St noted in an update dated September 16, 2026, the shares recently closed at USD 42.53, down 7.3 percent over the past month, while the three-year total shareholder return has declined 51.7 percent.

Capital Markets Day and valuation gap draw attention

According to Simply Wall St on September 16, 2026, Novo Nordisk has rebranded under the shorter name Novo and is preparing a detailed strategy update at its Capital Markets Day scheduled for September 21, 2026. The same analysis highlights that the share price of USD 42.53 sits well below a frequently cited fair value narrative of USD 102.97 per share, implying a valuation gap of roughly 58 percent between current pricing and perceived fundamental worth.

A separate valuation view from Yahoo Finance on September 17, 2026, cites a fair value estimate of USD 102.97 against a last close of USD 41.71, reinforcing the idea that the stock trades at a substantial discount to long-term growth expectations. That piece also notes that the seven-day share price return was down 6.4 percent and the year-to-date return down 20.39 percent, underlining that Novo Nordisk has recently lagged its earlier momentum in the GLP-1 obesity and diabetes market.

Share repurchase programme adds support

Alongside the upcoming Capital Markets Day, Novo Nordisk is using its balance sheet to support shareholders through a large-scale buyback. In a share repurchase update released from Bagsvaerd on September 14, 2026, the company reported that between September 7 and September 11, 2026, it bought back 1,050,000 B shares at average prices ranging from DKK 278.62 to DKK 297.98, corresponding to transaction values between DKK 58.5 million and DKK 62.6 million per day. According to this Globenewswire via Ritzau release, the accumulated purchases under the current programme reached 18,325,000 B shares with a total transaction value of DKK 5,526,186,488.

The same document states that as of September 11, 2026, Novo Nordisk owned 47,124,876 B shares as treasury shares, corresponding to 1.1 percent of the 4,465,000,000 total A and B shares outstanding. In addition, from February 4, 2026 to September 11, 2026, the company had repurchased a total of 33,084,179 B shares at an average share price of DKK 281.89, equal to a cumulative transaction value of DKK 9,326,186,478. For investors, these figures show that the company has been an active buyer of its own stock in 2026, even as the market price has eased from earlier peaks.

AI collaboration with Anthropic expands innovation story

On the strategic side, Novo Nordisk is also moving to deepen its use of artificial intelligence in drug discovery and software development. As GuruFocus reported on September 17, 2026, the company announced a collaboration with U.S. AI firm Anthropic to use its Claude Science platform to accelerate drug discovery and improve internal software tools. That analysis applies GuruFocus' GF Value metric to Novo Nordisk and arrives at an intrinsic value estimate of USD 390.22 per share versus a cited market price of USD 213.90, implying that the stock would be 45.2 percent undervalued relative to that model.

Another GuruFocus article dated September 16, 2026 focuses on Novo Nordisk's income profile and argues that the shares look 59.5 percent undervalued when comparing a GF Value of USD 105.13 per American depositary receipt with a current price of USD 42.53. According to this GuruFocus piece, Novo Nordisk offers a dividend yield of 4.22 percent with a payout ratio of 50 percent and a three-year dividend growth rate of 27.8 percent, which together support the thesis that the company can sustain and grow shareholder distributions.

Recent performance, analyst stance and upcoming date

Despite these supportive signals, short-term price action has been subdued. The Yahoo Finance overview on September 17, 2026 notes that at a share price of USD 41.71, Novo Nordisk's seven-day share price return stood at negative 6.4 percent and its one-year total shareholder return at negative 25.89 percent. Investors are therefore weighing the perceived mispricing suggested by fair value models against an observable period of weaker share performance.

On the home market, analyst houses have taken a cautious stance. An update on UBS research published by Zonebourse on September 17, 2026 states that UBS maintains its neutral recommendation on Novo Nordisk and keeps its price target at DKK 332. In the same market data context, the last closing price on Nasdaq Copenhagen is given as DKK 272.60, implying that the UBS target stands about 21.8 percent above the latest close, while a broader average price target is cited at DKK 310.17, still meaningfully higher than the actual trading level.

Looking ahead, the Capital Markets Day on September 21, 2026 is the next clearly defined strategic event. Simply Wall St highlights that this meeting will detail Novo Nordisk's refreshed strategy under its new slogan 'Lasting Health Starts Now' and its internal cultural framework 'The Novo Way'. For shareholders, the combination of an extensive buyback programme, AI collaboration and strategy update offers a concrete set of checkpoints against which to judge whether the current discount to fair value can narrow.

Stock price on Nasdaq Copenhagen

Novo Nordisk's primary listing for its B shares is on Nasdaq Copenhagen, where the stock most recently closed at DKK 272.60 on September 16, 2026, per market data referenced by Zonebourse for the Copenhagen exchange. That closing level sits below the cited average analyst price target of DKK 310.17 and well under the UBS target of DKK 332, underscoring that, for now, Novo Nordisk stock trades with a measurable gap to the valuations used by several external models and analysts.

More news and analyses on Novo Nordisk stock